Abbott Laboratories has raised its dividend for 54 consecutive years, with the latest quarterly payout set at $0.740243 per share, yielding 2.76%. In Q1 2026, the company reported total revenue of $11.16 billion, up 7.8% year-over-year, driven by its Medical Devices segment which grew 13.2% to $5.54 billion. The FreeStyle Libre continuous glucose monitor franchise generated $2.08 billion in quarterly revenue, a 13.8% increase, while the $21 billion Exact Sciences acquisition closed in March 2026, adding Cologuard and Cancerguard to its diagnostics portfolio. Abbott shares are trading at $90.53, down 30.67% over the past year and well below the analyst target of $116.54, with management guiding full-year 2026 adjusted EPS of $5.38 to $5.58.
Abbott LaboratoriesAbbott raised its dividend for the 54th consecutive year, signaling financial strength and returning capital to shareholders.
NVIDIA Corporation